R K D Pharmaceutical LLP is a globally focused pharmaceutical export and healthcare sourcing company providing access to high-quality pharmaceutical formulations, APIs, excipients, nutraceuticals, medical devices, surgical consumables, laboratory ins...
- (+91) 9004316713
- ajay.sharma@rkdpharmaceutical.com
- Unit no.414, 4th Floor, Marathon Max, Mulund – Goregaon Link road, Mulund West, , Mumbai, Maharashtra, India. 400080
© 2020 R K D PHARMACEUTICAL LLP. All Rights Reserved
Antibiotic Or Anti-Infective
Amoxicillin Trihydrate BP 875 mg & Potassium Clavulanate BP 125 mg
Strength & Pharmacopoeial Grade
Amoxicillin Trihydrate BP 875 mg & Potassium Clavulanate BP 125 mg is a fixed-dose antibacterial combination intended for oral tablet formulations. Each stated dose provides amoxicillin equivalent to 875 mg as amoxicillin trihydrate and clavulanic acid equivalent to 125 mg as potassium clavulanate. Pharmaceutical and institutional buyers should verify the finished-product specification, batch certificate of analysis (COA), registration status and applicable supply documentation before procurement.
Composition & Product Characteristics
The formulation combines a penicillin-class antibacterial, amoxicillin, with clavulanic acid supplied as potassium clavulanate, a beta-lactamase inhibitor. Procurement assessment should cover identity, assay, related substances, dissolution, microbial quality, tablet characteristics and packaging integrity against the approved specification. Excipients, storage conditions, pack configuration and market-specific labelling should be confirmed from the manufacturer’s technical dossier and batch documentation.
Amoxicillin Trihydrate BP 500 mg & Potassium Clavulanate BP 125 mg
Strength, Dosage Form & Pack Configuration
Amoxicillin Trihydrate BP 500 mg & Potassium Clavulanate BP 125 mg is a fixed-dose combination presented for institutional procurement. The summary highlights the combination identity, strength pairing and pack format considerations. Procurement teams should confirm blister counts, labeling and any local registration requirements.
Dosage-Form-Specific Handling & Administration Context
Follow product label guidance for administration and storage. Buyers should confirm any shelf-life, reconstitution or cold‑chain needs per the supplied product documentation before placing bulk orders.
Ciprofloxacin Tablets USP 500 mg
Strength, Dosage Form & Pack Configuration
Ciprofloxacin Tablets USP 500 mg is a finished oral dosage product listed by strength and form for procurement teams. The summary underlines pack configuration, labeling and institutional use. Buyers should confirm blister/bottle choices and regulatory labeling needs prior to ordering.
Dosage-Form-Specific Handling & Administration Context
Follow label instructions for administration and storage. Procurement should confirm shelf-life and handling requirements with the supplier to ensure compatibility with institutional inventory management.
Azithromycin Tablets BP 250 mg
Strength, Dosage Form & Pack Configuration
Azithromycin Tablets BP 250 mg are provided as a finished dosage form and listed for procurement. The summary emphasizes pack configuration, strength and suitability for institutional dispensing. Buyers should confirm labeled pack counts and storage recommendations when arranging bulk supply.
Dosage-Form-Specific Handling & Administration Context
Storage and handling follow product label guidance; confirm shelf-life details and any required documentation prior to ordering in bulk.
Azithromycin Tablets BP 500 mg
Strength, Dosage Form & Pack Configuration
Azithromycin Tablets BP 500 mg are listed as a finished dosage formulation with the BP reference in the title. The summary highlights strength, pack choices and institutional suitability. Procurement should confirm blister vs bottle packing and labelling needs prior to ordering.
Dosage-Form-Specific Handling & Administration Context
Follow label guidance for administration and storage. Buyers should request shelf-life and batch documentation details during quote stage to confirm compliance with institutional requirements.
Paracetamol Tablets 500mg
Active Strength & Dosage Form
Paracetamol Tablets 500mg are oral solid-dose products containing 500 mg of paracetamol in each tablet. Paracetamol is an analgesic and antipyretic active ingredient used for the symptomatic relief of pain and fever. Pharmaceutical distributors and institutional buyers should verify the dosage-form specification, applicable pharmacopoeial standard, batch certificate of analysis (COA) and destination-market authorization before procurement.
Composition & Product Characteristics
Each tablet contains 500 mg of paracetamol together with formulation-specific excipients required for manufacturing, stability and tablet performance. Technical evaluation should cover identification, assay, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity against the approved finished-product specification. Tablet appearance, excipient composition, pack configuration and storage requirements must be confirmed from the manufacturer’s product dossier and batch documentation.
Aceclofenac 100mg & Paracetamol 500mg Tablets
Active Strength & Dosage Form
Aceclofenac 100mg & Paracetamol 500mg Tablets are fixed-dose oral tablets containing 100 mg of aceclofenac and 500 mg of paracetamol per unit. The combination brings together aceclofenac, a non-steroidal anti-inflammatory drug, and paracetamol, an analgesic and antipyretic ingredient. Pharmaceutical distributors and institutional procurement teams should verify the dosage-form specification, batch certificate of analysis (COA), prescription classification and destination-market authorization before purchasing.
Composition & Product Characteristics
Each tablet contains aceclofenac 100 mg and paracetamol 500 mg together with formulation-specific excipients used to support manufacturing and tablet performance. Finished-product assessment should cover identification and assay of both active ingredients, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity. Tablet coating, appearance, excipient composition, storage conditions and pack configuration should be confirmed through the manufacturer’s approved specification and technical documentation.
Cetirizine Hydrochloride Tablets BP 10 mg
Active Strength & Pharmacopoeial Grade
Cetirizine Hydrochloride Tablets BP 10 mg are oral antihistamine tablets containing 10 mg of cetirizine hydrochloride per unit. The BP designation indicates that the product is intended to comply with the applicable British Pharmacopoeia requirements. Pharmaceutical distributors and institutional buyers should verify the finished-product specification, batch certificate of analysis (COA), market authorization and supporting pharmacopoeial documentation before procurement.
Composition & Product Characteristics
Each tablet contains 10 mg of cetirizine hydrochloride together with formulation-specific excipients used to support manufacturing, stability and tablet performance. Technical assessment should cover identification, assay, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity against the approved specification. Tablet coating, appearance, scoring, excipient composition and storage requirements should be confirmed from the manufacturer’s technical dossier and batch documentation.
Levocetirizine Dihydrochloride Tablets USP 10 mg
Active Strength & Pharmacopoeial Grade
Levocetirizine Dihydrochloride Tablets USP 10 mg are presented as oral antihistamine tablets containing the stated strength of levocetirizine dihydrochloride. The USP designation indicates intended alignment with applicable United States Pharmacopeia requirements. Because commonly authorized levocetirizine tablet products are documented at 5 mg, buyers should specifically verify the stated 10 mg strength through the manufacturing license, finished-product specification, batch certificate of analysis (COA) and destination-market authorization.
Composition & Product Characteristics
The stated formulation contains levocetirizine dihydrochloride together with product-specific excipients required for tablet manufacture, stability and performance. Technical procurement should assess active-ingredient identity and assay, related substances, dissolution, disintegration, uniformity of dosage units, microbial quality and packaging integrity. Tablet appearance, coating, scoring, excipient composition, storage conditions and pack configuration should be confirmed from the manufacturer’s approved dossier and batch documentation.
Cefixime for Oral Suspension USP 100mg (60ml)
Strength, Dosage Form & Pack Configuration
Cefixime for Oral Suspension USP 100mg (60ml) is listed for pharmacy and clinical procurement. The summary emphasises the provided strength and pack size. Buyers should confirm labeling, dispensing instructions and any required package inserts.
Dosage-Form-Specific Handling & Administration Context
Follow label instructions for storage and administration. Confirm any post‑reconstitution shelf life or handling recommendations from the product documentation prior to clinical use.
Cefuroxime Axetil for Oral Suspension USP 125 mg (100ml)
Strength, Dosage Form & Pack Configuration
Cefuroxime Axetil for Oral Suspension USP 125 mg (100ml) is presented for pharmacy procurement. The block highlights the strength and container pairing as provided in the product title. Buyers should confirm pack labelling and dispensing instructions where required.
Dosage-Form-Specific Handling & Administration Context
Oral suspension handling and storage should follow the product label. Reconstitution or post‑opening stability instructions must be confirmed from the supplied product documentation prior to dispensing in clinical settings.
Cefpodoxime Proxetil for oral suspension 50 mg (100ml)
Strength, Dosage Form & Pack Configuration
Cefpodoxime Proxetil for oral suspension 50 mg (100ml) is offered for pharmacy procurement. The summary highlights the product's strength and container pairing. Buyers should confirm dispensing labels and pack configurations before purchase.
Dosage-Form-Specific Handling & Administration Context
Storage and administration follow the product label; confirm any post‑reopening stability or reconstitution guidance from supplied documentation prior to clinical use.
Ceftriaxone 250 mg Injection
Active Strength & Injectable Presentation
Ceftriaxone 250 mg Injection is generally presented as a sterile powder containing ceftriaxone sodium equivalent to 250 mg of ceftriaxone in a single-dose vial. The powder requires reconstitution with an approved diluent before administration by a qualified healthcare professional. Hospital and institutional buyers should verify the pharmacopoeial standard, route of administration, batch certificate of analysis (COA), sterility documentation and destination-market authorization before procurement.
Composition & Physicochemical Properties
The vial contains ceftriaxone in the form of ceftriaxone sodium, typically supplied as a white to yellowish crystalline powder for solution for injection. Technical evaluation should cover identification, potency, related substances, water content, particulate matter, sterility, bacterial endotoxins and container-closure integrity against the approved specification. Compatible diluents, reconstitution instructions, solution stability and administration conditions must be confirmed from the manufacturer’s approved product information.
Ceftriaxone 500 mg Injection
Assay Purity & Pharmacopoeial Grade
Ceftriaxone 500 mg Injection is provided as an active-strength listing without an explicit dosage form. The summary focuses on assay verification, impurity profile and procurement suitability for formulation or institutional use. Buyers should request COA to verify batch parameters before acceptance.
Composition & Physicochemical Properties
The SKU identifies the active at the stated strength. Procurement assessments should confirm intended presentation and any sterility or packaging needs with the supplier to ensure compatibility with downstream processes.
Ceftriaxone 1000 mg Injection
Assay Purity & Pharmacopoeial Grade
Ceftriaxone 1000 mg Injection is listed as the active strength without an explicit dosage form in the product title. The summary treats this entry as the active-strength SKU and focuses on procurement checks such as assay, impurity profile and batch documentation. Buyers should request COA to verify assay and related QC parameters.
Composition & Physicochemical Properties
The entry denotes the active compound at the given strength. Procurement evaluation should consider solubility, handling and any sterility requirements if the intended use is injectable; confirm form and presentation with the supplier.
Ceftriaxone & Sulbactam for Injection 1.5 g
Strength, Dosage Form & Pack Configuration
Ceftriaxone & Sulbactam for Injection 1.5 g denotes the combination strength intended for injectable preparation. The summary concentrates on the combination identity and procurement considerations for clinical inventories. Buyers should confirm vial count and presentation as part of purchase planning.
Dosage-Form-Specific Handling & Administration Context
Injectable handling and administration must follow product labeling and local clinical protocols. Confirm diluent compatibility, reconstitution instructions and cold‑chain requirements from supplied product documentation when applicable.
